Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

608
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
608
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

558
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
558
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

83
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
83
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.1K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oncovascular Resection in Pelvic Exenteration: A Systematic Review.

ANZ journal of surgery·2026
Same author

The Role of Pelvic Reirradiation in the Treatment of Locally Recurrent Rectal Cancer: A Systematic Review.

Biomedicines·2026
Same author

How Much Does It Cost to Become a Colorectal Surgeon? A Cost Comparison of Training in the United States, Australia and New Zealand, and United Kingdom.

Diseases of the colon and rectum·2026
Same author

The Tumour Immune Microenvironment as a Predictor of the Response to Neoadjuvant Therapy in Rectal Cancer.

Cancers·2026
Same author

The Cost-Effectiveness of Conservatively Managed Acute Appendicitis Versus Appendicectomy: A Systematic Review.

Surgical laparoscopy, endoscopy & percutaneous techniques·2026
Same author

An evaluation of 3D modelling in patients with locally advanced pelvic malignancy undergoing surgical resection.

Frontiers in oncology·2026

Related Experiment Video

Updated: Mar 6, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.1K

Re-examining HSPC1 inhibitors.

Sheah Lin Lee1,2, Nina Claire Dempsey-Hibbert3,4, Dale Vimalachandran5

  • 1Chester Centre for Stress Research, Institute of Medicine, University of Chester, Bache Hall, CH2 1BR, Chester, UK. lee.sheahlin@gmail.com.

Cell Stress & Chaperones
|March 4, 2017
PubMed
Summary

Heat shock protein client 1 (HSPC1) inhibitors show varied effectiveness in colorectal cancer (CRC) treatment. Despite common mechanisms, distinct differences exist between inhibitors, impacting combination therapy outcomes and patient sensitivity.

Keywords:
ChemoresistanceChemotherapyColorectal cancerHeat shock proteinsNovel targetTumour evolvability

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

7.0K

Related Experiment Videos

Last Updated: Mar 6, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.1K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.7K
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

7.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Heat shock protein client 1 (HSPC1) is crucial in cancer development, including colorectal cancer (CRC).
  • Clinical efficacy of HSPC1 inhibitors has been inconsistent, with variations among N-terminal inhibitors.
  • Understanding these differences is key to optimizing CRC treatment strategies.

Purpose of the Study:

  • To investigate the distinct effects of three N-terminal HSPC1 inhibitors (17-DMAG, NVP-AUY922, NVP-HSP990) on colorectal cancer cells.
  • To evaluate the efficacy of these inhibitors in combination with standard CRC chemotherapeutic agents.
  • To explore the role of anti-apoptotic proteins HSPA1A and HSPB1 in treatment resistance.

Main Methods:

  • Treatment of CRC cells with individual HSPC1 inhibitors and assessment of client protein degradation over time.
  • Combination therapy experiments using HSPC1 inhibitors with 5-fluorouracil, oxaliplatin, and irinotecan.
  • Gene-silencing techniques to investigate the role of HSPA1A and HSPB1 in treatment resistance.

Main Results:

  • Distinct differences in client protein degradation timelines were observed among the three HSPC1 inhibitors.
  • 17-DMAG demonstrated superior potentiation of chemotherapeutic agent cytotoxicity compared to NVP-AUY922.
  • Gene silencing of HSPA1A or HSPB1 did not improve sensitivity to HSPC1 inhibitors or chemotherapeutic agents.

Conclusions:

  • N-terminal HSPC1 inhibitors exhibit significant variability in their effects on CRC cells and in combination therapy.
  • HSPC1 inhibitors enhance the cytotoxic effects of standard CRC chemotherapeutics, presenting a viable clinical trial approach.
  • Individual patient variability in sensitivity to HSPC1 inhibitors necessitates further translational research.